Conclusion: Mobius correctly calculated dose for each tested intensity modulated treatment plan, agreeing with measurement to within 3.5% for all cases analyzed.
| INTRODUCTION
Mobius3D and MobiusFX are two components of the Mobius second-check dosimetry system produced by Mobius Medical Systems (Mobius Medical Systems, Houston, TX, USA). Mobius3D performs a full recalculation of dose on the patient CT-dataset using treatment parameters exported from the primary treatment planning system (TPS) and an independent convolution-superposition algorithm. 1 MobiusFX allows for quality assurance of the treatment plan by offering a "delivered dose" calculation, generated using the Mobius3D model and delivery log files produced by the treatment machine. In addition, the MobiusFX module provides automatic "delivered dose" calculation on the Mobius Verification Phantom (MVP).
The MVP is a Virtual Water TM dosimetry phantom with seven predetermined ionization chamber positions for absolute dose measurement. The expected dose at each of these chamber positions is automatically calculated in the MobiusFX module, using the Mobius3D beam model and treatment delivery log files. For the purposes of this work, both the MobiusFX and Mobius3D modules will be referred to as "Mobius".
In order for a second-check dosimetry system to provide useful information to the user, the user must have confidence in the ability of the second-check system to accurately calculate dose. While second-check systems are not expected to approach the dosimetric accuracy of the primary TPS, their accuracy must be such that the number of "false positives" produced does not obscure any true problems with the primary TPS. Ideally, a treatment plan failing a second-check dosimetry calculation should be an unusual occurrence, prompting a thorough investigation. If the second-check system lacks the ability to accurately calculate dose for complex modern treatment plans, failures will be routine and indeterminate, rendering the second-check largely meaningless. 
2.B | Plan selection
For pre-clinical validation, 17 anonymized intensity-modulated treatment plans were selected for analysis. All plans were generated in Table 1 .
For the post-implementation clinical plan comparison, the first 36 treatment plans evaluated using Mobius were chosen for inclusion in this study. The only requirement for inclusion was intensity modulation; this included IMRT as well as VMAT. Of these 36 clinical cases, 33 used a beam energy of 6 MV, one used a beam energy of 10 MV, and two used mixed energy (6 and 10 MV). to chamber position C for this beam geometry was calculated by hand using machine commissioning data. This expected dose and the charge collected were used to determine a dose to charge ratio. This process was performed for both the 6 and 10 MV beams.
2.C |
Intensity modulated plans were then delivered. Measured charge and the previously calculated dose to charge ratios were used to determine measured dose. Each plan was delivered twice, so that dose could be measured for each plan at each of the two selected chamber positions. The 6 and 10 MV portions of mixed-beam IMRT plans were measured separately, then summed to determine total dose.
2.E | Pre-clinical validation: determination of phantom dose in Mobius
The seventeen selected treatment plans were individually exported from Eclipse to the Mobius second-check system (v1.5.3). Upon receiving the necessary DICOM information (CT-dataset, RT plan, structure set, and dose), Mobius automatically began a secondary dose calculation on the patient CT using its independent convolution-superposition algorithm. Treatment log files, generated by the Overall, we found AcurosXB to be consistently low compared to measurement with the MVP, while Mobius dose differences were more varied. This is likely due to tuning of the DLG correction factor in Mobius. This correction factor was adjusted based on ionization chamber measurements, similar to those undertaken in this study, in an effort to create an even distribution of dose differences as calculated by Mobius. The success of this tuning can be seen in the results presented here: the average difference from Mobius to ion chamber measurement is near zero. However, the standard deviation of the Mobius differences was higher compared to the AcurosXB.
Data input for the AcurosXB calculation model is more complex, and the algorithm was tuned using a variety of available information, including beam profiles, ionization-chamber point measurements, gafchromic film measurements, and diode array measurements. In addition, AcurosXB is optimized for a large variety of clinical treatment scenarios. For these reasons, we are not surprised to see minor, more consistent, differences between AcurosXB calculations and point-doses measured in the MVP.
Neither treatment technique, nor beam energy, had a significant effect on the differences seen between Eclipse AcurosXB and measurement. 6 MV VMAT plans showed an average difference of À1.4 AE 0.5%, while 10 MV VMAT plans showed an average difference of À1.7 AE 1.0%. 6 MV IMRT, 10 MV IMRT, and mixed-beam IMRT show average differences of À1.1 AE 0.3%, À0.8 AE 0.3%, and MLC model. Numerous studies have been done examining the accuracy of the AcurosXB calculation algorithm and Eclipse MLC model, and point to its accuracy in a variety of clinical situations. [22] [23] [24] [25] Despite the use of stock beam data, the Mobius dose calculation algorithm was capable of matching the measured dose within 3.5% for all measured cases.
3.B | Pre-clinical validation: Mobius vs. AcurosXB test case analysis
For each of the 17 previously delivered plans, TPS dose calculated with the AcurosXB algorithm was compared directly to dose calculated in Mobius on the patient CT-dataset. The target mean dose percent difference, target D95% percent difference, 3D global gamma pass rate, and target gamma pass rate for each of the 17 analyzed plans can be found in Table 3 . For reported percent differences, a positive percent difference indicates that Mobius calculated a higher number for a given statistic. For both the 3D global and target gamma pass rates, gamma criteria of 3%/2 mm were used.
Mobius tended to report a higher target mean dose than AcurosXB, with an average target mean dose percent difference of 1.0 AE 1.1%.
Target mean dose differences ranged from À1.2 to 2.6%. Mobius tended to report a lower target D95% than AcurosXB, with an average target D95% difference of À0.9 AE 2.0%. Target D95% percent differences ranged from À4.4 to 2.4%. 3D global gamma pass rates ranged from 87.9 to 99.9%, with an average value of 94.4 AE 3.3%.
Gamma pass rate for the target-only ranged from 58.5 to 98.6%, with an average value of 80.2 AE 12.3%.
Mobius tended to report a less homogeneous dose to the target compared to AcurosXB. were examined for the typical areas of disagreement outlined in the previous section. Of the two cases with target gamma pass rates below 90%, one involved a small PTV at the skin surface. The other case involved a small, low-density lung PTV near a rib. Due to expected differences in the build-up region, and at heterogeneous interfaces, the target gamma pass rate was affected significantly in each case. All differences were as expected, based on the pre-clinical test cases.
| CONCLUSION
The Mobius second check system was validated for a variety of intensity modulated clinical treatment plans, using the recently released MVP and an ADCL-calibrated ionization chamber. We found that Mobius performed well compared to the AcurosXB dose calculation algorithm, implemented in our clinical treatment planning system, Eclipse. Mobius differences from measured dose were reasonable, especially in the context of a second check system utilizing a non-customized beam model. We feel that intensity modulated plans can be safely verified using the Mobius system, and that extreme differences between Mobius and Eclipse would rightly 
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